High burden of viruses and bacterial pathobionts drives heightened nasal innate immunity in children with and without SARS-CoV-2

Recent work indicates that heightened nasal innate immunity in children may impact SARS-CoV-2 pathogenesis. Here, we identified drivers of nasal innate immune activation in children using cytokine profiling and multiplex pathogen detection in 291 pediatric nasopharyngeal samples from the 2022 Omicron surge. Nasal viruses and bacterial pathobionts were highly prevalent, especially in younger children (81% of symptomatic and 37% asymptomatic children overall; 91% and 62% in subjects <5 yrs). For SARS-CoV-2, viral load was highest in young children, and viral load in single infections or combined viral loads in coinfections best predicted nasal CXCL10, a biomarker of the mucosal interferon response. Bacterial pathobionts correlated with high nasal IL-1 beta and TNF, but not CXCL10, and viral-bacterial coinfections showed a combined immunophenotype. These findings reveal virus and bacteria as drivers of heightened nasal innate immunity in children and suggest that frequent host-pathogen interactions shape responses to respiratory viruses in this age group


Introduction
the nasal mucosa without rhinovirus infection, although the presence of viruses was not To explore TNF and IL-1β as biomarkers of the mucosal innate immune response level, further suggesting pathobiont load is a driver of IL-1β level (r 2 =0.2843, p<0.0001; 1 9 0 r 2 =0.2562, p<0.0001) (Fig 5C-D). TNF level correlated significantly with pathobiont load in both 1 9 1 virus-positive and virus-negative samples, and the slope of virus-positive samples trended 1 9 2 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 20, 2023. slightly higher, but the difference was not significant (p=0.1105) (Fig 5E). These data suggest 1 9 3 that nasopharyngeal IL-1β and TNF reflect a pathobiont-induced mucosal inflammatory 1 9 4 response that occurs independently of, but may be enhanced by, viral coinfection. 1 9 5 We also explored the impact of pathobiont detection on nasal CXCL10 in the same four 1 9 6 groups. Consistent with the sample set as a whole (Fig 2), in children <5 years, we observed 1 9 7 significant elevation in nasal CXCL10 in virus-positive samples compared to virus-and 1 9 8 pathobiont-negative controls regardless of pathobiont detection, but no CXCL10 elevation in 1 9 9 pathobiont-positive, virus-negative subjects. (Fig 5F). When limiting the analysis to negative subjects, although asymptomatic subjects had lower viral loads and CXCL10 levels 2 0 2 than symptomatic subjects (Fig S3A-B). Together, these data provide evidence that a robust  Since pathobionts are associated with clinically significant secondary infections following 2 0 6 viral infection, we also explored the relationship between pathobiont detection and viral load. loads did not correlate with each other in codetections (Fig S3C-E). We also did not observe a 2 1 0 significant change of nasal immunophenotypes defined by IL-1β, TNF, and CXCL10 levels 2 1 1 attributed to patient sex in this age group (Fig S4A-C). Together, these findings indicate that 2 1 2 both viruses and bacterial pathobionts promote heightened nasal innate immunity in young 2 1 3 children, and that viruses and pathobionts drive distinct patterns of heightened nasal innate 2 1 4 immunity. Biomarkers demonstrate heightened nasal innate immunity in children <5 years old with 2 1 7 distinct patterns related to viral and bacterial pathobiont burden. 2 1 8 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) immunophenotypes in children <5 years of age, we generated scatterplots based on 2 2 0 concentrations of CXCL10 and IL-1β, the nasopharyngeal biomarkers best associated with viral 2 2 1 infection and bacterial pathobionts respectively. Within the 0-5 years age group, age did not 2 2 2 appear to correlate with cytokine responses (Fig 5G). In contrast, plots highlight a strong 2 2 3 association between viral load and nasopharyngeal CXCL10 and between bacterial load and nasopharyngeal IL-1β (Fig 5H-I). Children presenting to the E.D. with symptoms of acute 2 2 5 respiratory infection separated into a CXCL10-high and IL-1β low-to-high phenotype, indicating that viral infection was highly associated with symptomatic presentation (Fig 5J). Among virus- positive subjects <5 years old, symptomatic subjects and asymptomatic subjects were equally 2 2 8 likely to be pathobiont-positive suggesting that pathobiont detection was not a strong influence on symptomatic presentation (Table S2). However, virus-positive, pathobiont-positive subjects 2 3 0 did have an enhanced mucosal inflammatory response as indicated by trend toward higher 2 3 1 nasal TNF in subjects with viral/pathobiont codetection compared to those with virus or 2 3 2 pathobiont only (Fig 5B, E). Taken together, these analyses show that viruses and nasal 2 3 3 bacterial pathobionts are associated with distinct patterns of heightened mucosal innate 2 3 4 immunity, alone and in combination, compared to age-matched virus-negative, bacteria-  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Innate immune defenses at the site of infection are critically important in limiting 2 3 8 susceptibility to respiratory viruses, particularly in the case of emerging viruses such as SARS- 2 3 9 CoV-2 when there is no prior adaptive immunity. Here we show a clear relationship between studies, these results point to a high burden of respiratory viruses and bacterial pathobionts in 2 4 4 children and link these mucosal pathogens with heightened nasal innate immunity. Our results 2 4 5 also highlight examples of viral-viral and viral-bacterial coinfections which illustrate that the host 2 4 6 response to one microbe influences the mucosal response to another in the airway niche.

4 7
A key feature of our study was performing PCR testing targeting 15 seasonal respiratory  adults. However, basal cells cultured in vitro from the same subjects showed a trend toward with our findings indicating that viruses and bacteria found in the nasal mucosa in vivo, rather 3 0 7 than cell-intrinsic factors, drive heightened respiratory mucosal innate immunity in children. In addition to heightened interferon responses, prior studies using scRNA-seq of patient samples showed that the pediatric nasal mucosal was enriched for leukocytes, particularly  bacterial pathobionts compared to pathobiont-low ,rhinovirus-infected subjects, associated with  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 20, 2023. ; https://doi.org/10.1101/2023.06.17.23291498 doi: medRxiv preprint 1β and TNF as biomarkers of pathobiont-associated inflammation in both virus-negative and 3 1 5 virus-positive subjects. Pathobionts alone did not induce nasal interferon responses, as indicated by no change in the CXCL10 level, but were associated with a synergistic increase in 3 1 7 TNF. Together, these observations show that pathobionts promote local mucosal inflammatory 3 1 8 responses and may enhance antiviral responses upon viral coinfection. While our study shows a high frequency of pathobionts in young children, it is still  and Streptococcus increase the incidence of infection, disease severity during infection, risk of  years, but SARS-CoV-2+ samples in this age group were almost all from symptomatic subjects 3 2 7 with similar high viral loads. Evaluating this question with unbiased sampling, including 3 2 8 longitudinal studies on children with and without pathobionts at baseline, will provide more 3 2 9 insight into how pathobionts influence SARS-CoV-2 susceptibility and outcomes. Our study also demonstrated high prevalence of respiratory viruses in children and literature, our data support a model in which children are highly susceptible to respiratory 3 3 3 viruses but also that frequent host-virus interactions have a net effect of limiting closely spaced  from our group and others shows that prior infection with rhinovirus and other seasonal 3 3 7 respiratory viruses can induce a robust interferon response that reduces replication of SARS- CoV-2 or influenza viruses in simultaneous or sequential infections. 23,46-50 Also compelling is a 3 3 9 recent vaccination study by Costa-Martins et. al., which showed that among asymptomatic CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 20, 2023. the outcome of viral coinfections depends on many factors including the viruses involved, 3 4 4 relative timing, and host susceptibility, we propose that when the first infection is well-controlled 3 4 5 by the mucosal interferon response, the effect is likely to be protective, such as in the setting of 3 4 6 asymptomatic or resolving viral infections that are common in young children. 3 4 7 In sum, this qualitative and quantitative analysis of respiratory viruses, bacterial 3 4 8 pathobionts, and cytokine biomarkers reveals viruses and bacterial pathobionts as major drivers 3 4 9 of heightened nasal innate immunity in children and compels further study of how seasonal interactions occurring in asymptomatic subjects. Limitations of the study 3 5 4 Here we measured a targeted panel of cytokine biomarkers, viruses and bacteria in a large 3 5 5 sample set, complementing prior work which used detailed immunophenotyping by RNA-seq 3 5 6 and single cell sequencing albeit in smaller sample sets. We focused on 19 respiratory 3 5 7 microbes, but other less common viruses or nasopharyngeal pathobionts could also contribute 3 5 8 to nasal innate immune activation in children. Future studies pairing detailed 3 5 9 immunophenotyping with sensitive pathogen detection methods and clinical data will provide  Additionally, this analysis captured only a small number of viral coinfections with SARS-CoV-2 3 6 2 which suggested that viral coinfections augment the interferon response to SARS-CoV-2, but further studies are required for confirmation. Finally, we studied a cross-section of samples from immunophenotypes in children impact SARS-CoV-2 infection in will provide further insights into 3 6 6 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 20, 2023. ; https://doi.org/10.1101/2023.06.17.23291498 doi: medRxiv preprint host-pathogen interactions and the consequences of heightened mucosal innate immunity in 3 6 7 children. 3 6 8 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Resource Availability
This study did not generate new unique reagents.

Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Ellen Foxman (ellen.foxman@yale.edu).

Data and code availability
All data produced in the present work are contained in the manuscript. Extended data analyses, original code for mediation analysis and data visualizations, and extended demographics data will be deposited in Mendeley Data at the DOI 10.17632/g8ckr9zxbx.1 and will be available at the time of peer-reviewed publication.

Nasopharyngeal swab collection and inclusion criteria
In this study, we collected a total of 306 residual nasopharyngeal swab samples from patients presenting to the pediatric emergency department between January 11-23, 2022 and were screened for SARS-CoV-2. 15 samples were excluded from further analysis due to low Ct for the internal control (albumin, Ct>33), leaving 291 samples for analysis. The study protocol was reviewed and approved by the Yale Human Investigation Committee (protocol #2000027656) and was determined to not require specific patient consent.

Chart review for symptom designation and admission comorbidities
To assign symptoms, we extracted, de-identified ICD-10 codes and supplemented with manual chart review. Patients were considered "symptomatic" if the ICD-10 code associated with presentation to the ED are common in respiratory infections. For patients with acute, . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 20, 2023. ; symptomatic presentations related to respiratory infections, ICD-10 codes alone were used to ascribe clinical syndromic categories. Where ICD-10 codes for acute, symptomatic presentations were ambiguous (e.g., "Emergency use of U07.1 | COVID-19"), or for clinical samples which were obtained in the preoperative setting, manual chart review by a clinical reviewer blinded to bacterial, viral, and immune biomarker status was conducted for determination of clinical syndromic category. Detailed examination of patients positive for COVID-19 testing and admitted to the inpatient setting were characterized via manual chart review to determine presenting symptoms and comorbidities. In this latter instance, the clinician reviewer was blinded to bacterial status, common respiratory viral status, and biomarker status, but not COVID-19 status.

Cytokine measurements
Viral transport media was thawed on ice before measurement of cytokines and subsequently aliquoted and stored at -80°C for use in other experiments. CXCL10, IL-1β, and TNF proteins were measured using the Ella automated microfluidics system (Protein Simple, San Jose, USA).

Clinical Virology Testing
For testing by the YNHH Clinical Virology Laboratory, nasopharyngeal swabs were placed in viral transport media (BD Universal Viral Transport Medium) immediately upon collection for clinical SARS-COV-2 testing. Viral transport media associated with nasopharyngeal swasb was aliquoted and stored at -80°C for further analyses within three days of clinical testing. For virology testing, 200 μ L of VTM were used for total nucleic acid extraction using the NUCLISENS easyMAG platform (BioMérieux, France). Extracted nucleic acid was tested for a 15-virus panel as described previously. 24 SARS-CoV-2 testing was completed using four clinical testing platforms. When the clinical testing platform did not result in a Ct value for SARS-CoV-2 or the value was unable to be retrieved from medical records, we performed in-lab SARS-CoV-2 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. where only the Ct value of the SARS-CoV-2 test was considered. We followed Baron and Kenny's causal step approach using linear modelling of the effect. 26 Pre-requisites for indicating the appropriateness of the mediation analysis were confirmed by testing for a significant direct effect from the independent variable (IV; i.e., age) towards the dependent variable (DV; i.e., is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 20, 2023. ; https://doi.org/10.1101/2023.06.17.23291498 doi: medRxiv preprint software (QIAGEN Digital Insights) and Qlucore Omics Explorer (Qlucore) were used to generate graphs and heatmaps. All figures were edited and arranged in Adobe Illustrator (Adobe Inc, Mountain View, CA, USA).

RNA-seq Analysis of GSE172274
RNA-seq analysis of samples deposited in the NIH Gene Expression Omnibus (GEO) database under the accession number GSE172274 was carried out using Partek Flow software (version 10.0) for human transcripts. 2 Samples were aligned to the GRCh38 human genome using Bowtie 2 and quantified using Ensembl Transcripts Release 104. 27,28,57 Counts were normalized as counts per million (CPM) plus 0.0001 for downstream log-scaling analysis. Analysis focused on 50 genes found to be upregulated and differentially expressed in nasal epithelial cells during the antiviral response from a previous dataset. 22 Normalized counts were converted to Z-scores by subtracting the mean expression of each gene across all sample from each sample count and dividing by the standard deviation of the gene's expression across all samples. Finally, the ISG score was calculated by averaging the Z-scores for the 50 listed genes for each sample.
Metatranscriptomics analysis of samples in GSE172274 were analyzed using the CZ ID metatranscriptomics pipeline as previously described. 24,29 Non-SARS-CoV-2 respiratory virus reads were considered positive if above 1 read per million (rPM). All samples in this dataset tested positive for SARS-CoV-2 by clinical testing as described previously. 2

RNA-seq analysis was performed on datasets available on the NIH Database of Genotypes and
Phenotypes (dbGaP) under accession codes phs002442.v1.p1 and phs002433.v1.p1 as previously described. 23,24 Ingenuity pathway analysis (IPA) was carried out using differentially expressed genes (DEGs) between rhinovirus-positive/pathobiont-high and rhinoviruspositive/pathobiont-low samples to identify genes expressed in virus/pathobiont codetection. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 20, 2023.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.      Tables   Table 1: Results of multiplex virology testing by demographics, presentation, and pathobiont status.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 20, 2023. ; Correlation between CXCL10 (Log10 pg/mL) in virus-positive subjects (black line), virus negative subjects (grey line), and all subjects (dashed line). For A and C-H, shading represents 95% CI for regression line slope, r2 and p-value for correlation are shown. (B) Nasopharyngeal CXCL10 (Log10 pg/mL) in virus-positive and virus-negative subjects of all ages (n=291). P-value by Welch's t-test is shown. (C) CXCL10   The red asterisk denotes a patient with reads from attenuated measles vaccine virus. See Table S6 for additional information.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 20, 2023. ; https://doi.org/10.1101/2023.06.17.23291498 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 20, 2023.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 20, 2023. ; https://doi.org/10.1101/2023.06.17.23291498 doi: medRxiv preprint